Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have earned an average rating of “Moderate Buy” from the sixteen research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $35.9167.

A number of research analysts recently issued reports on the company. BTIG Research reiterated a “buy” rating and set a $39.00 price objective on shares of Denali Therapeutics in a research note on Monday, May 11th. Sanford C. Bernstein restated a “hold” rating on shares of Denali Therapeutics in a research note on Monday, June 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a report on Friday, July 17th. JPMorgan Chase & Co. initiated coverage on shares of Denali Therapeutics in a research report on Monday, July 13th. They issued an “overweight” rating and a $29.00 price target for the company. Finally, Wedbush reissued an “outperform” rating and issued a $26.00 price objective on shares of Denali Therapeutics in a research note on Monday, July 13th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Baillie Gifford & Co. lifted its position in shares of Denali Therapeutics by 6.2% in the fourth quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock valued at $203,253,000 after acquiring an additional 719,304 shares in the last quarter. B. Metzler seel. Sohn & Co. AG purchased a new stake in shares of Denali Therapeutics during the fourth quarter worth about $1,841,000. Pictet Asset Management Holding SA grew its position in shares of Denali Therapeutics by 166.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,329,108 shares of the company’s stock worth $21,981,000 after purchasing an additional 829,946 shares in the last quarter. UBS Group AG raised its stake in Denali Therapeutics by 19.5% during the 4th quarter. UBS Group AG now owns 2,404,704 shares of the company’s stock valued at $39,702,000 after purchasing an additional 392,351 shares during the period. Finally, E. Ohman J or Asset Management AB bought a new stake in Denali Therapeutics during the 2nd quarter valued at approximately $4,115,000. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Stock Performance

NASDAQ:DNLI opened at $25.27 on Friday. The stock has a 50-day simple moving average of $23.85 and a two-hundred day simple moving average of $21.43. Denali Therapeutics has a 52-week low of $12.58 and a 52-week high of $27.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37. The firm has a market capitalization of $4.04 billion, a PE ratio of -8.90 and a beta of 1.01.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The business had revenue of $3.60 million during the quarter, compared to analyst estimates of $2.15 million. During the same period last year, the firm posted ($0.72) EPS. Analysts forecast that Denali Therapeutics will post -2.61 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.